Authors:
Munck, A
Bonacorsi, S
Mariani-Kurkdjian, P
Lebourgeois, M
Gerardin, M
Brahimi, N
Navarro, J
Bingen, E
Citation: A. Munck et al., Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization, PEDIAT PULM, 32(4), 2001, pp. 288-292
Authors:
Duriez, P
Clermont, O
Bonacorsi, S
Bingen, E
Chaventre, A
Elion, J
Picard, B
Denamur, E
Citation: P. Duriez et al., Commensal Escherichia coli isolates are phylogenetically distributed amonggeographically distinct human populations, MICROBI-SGM, 147, 2001, pp. 1671-1676
Citation: O. Clermont et al., The Yersinia high-pathogenicity island is highly predominant in virulence-associated phylogenetic groups of Escherichia coli, FEMS MICROB, 196(2), 2001, pp. 153-157
Authors:
Iyer, RA
Mitroka, J
Malhotra, B
Bonacorsi, S
Waller, SC
Rinehart, JK
Roongta, VA
Kripalani, K
Citation: Ra. Iyer et al., Metabolism of [C-14] omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans, DRUG META D, 29(1), 2001, pp. 60-69
Authors:
Fitoussi, F
Loukil, C
Gros, I
Clermont, O
Mariani, P
Bonacorsi, S
Le Thomas, I
Deforche, D
Bingen, E
Citation: F. Fitoussi et al., Mechanisms of macrolide resistance in clinical group B streptococci isolated in France, ANTIM AG CH, 45(6), 2001, pp. 1889-1891
Authors:
Bonacorsi, S
Fitoussi, F
Lhopital, S
Bingen, E
Citation: S. Bonacorsi et al., Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis, ANTIM AG CH, 43(2), 1999, pp. 213-217